Jewish Telegraphic Agency4d
David Ben-Gurion’s message of resilience takes center stage Dec. 8
Americans in search of hope and optimism amid Israel’s multifront war as well as surging antisemitism on the home front can ...
The Forward25d
Is Elon Musk Jewish?
No. Next question. OK, we’ll indulge this a bit. Elon Musk’s first name is Hebrew. It was the name of one of the biblical judges. It’s also the name of unincorporated communities in Iowa and ...
Seeking Alpha29d
Lexicon Pharma in selloff as FDA AdCom rebukes diabetes drug (update)
Lexicon Pharmaceuticals (NASDAQ:LXRX) lost ~39% in the morning hours on Friday following a trading halt in the previous session as an FDA advisory committee declined to endorse its diabetes ...
FiercePharma29d
In FDA adcomm, Lexicon gets another thumbs down for type 1 diabetes hopeful Zynquista
Despite its unique ability to block sodium-glucose linked transporter 2 (SGLT2) in the kidneys and SGLT1 in the intestines, Lexicon’s Zynquista (sotagliflozin) has had difficulty negotiating ...
Benzinga.com29d
FDA Panel Rejects Lexicon's Zynquista For Type 1 Diabetes
In 2021, at Lexicon's request, the FDA issued a public Notice of Opportunity for Hearing (NOOH) on whether there were grounds for denying such approval. Lexicon and FDA subsequently agreed in late ...
Nasdaq1mon
FDA Panel Votes Against Lexicon's NDA For Zynquista In Type 1 Diabetes And Chronic Kidney Disease
(RTTNews) - Lexicon Pharmaceuticals Inc. (LXRX) announced that the U.S. Food and Drug Administration's Advisory Committee voted against the company's New Drug Application (NDA) for Zynquista ...
Reuters1mon
FDA advisers vote against Lexicon Pharma's add-on drug for type 1 diabetes
Oct 31 (Reuters) - Independent advisers to the U.S. Food and Drug Administration on Thursday voted against recommending Lexicon Pharmaceuticals' (LXRX.O), opens new tab add-on treatment to insulin ...
The Pharma Letter1mon
FDA panel vote leaves Lexicon’s Zynquista hopes hanging by a thread
Texas, USA-based biopharma Lexicon Pharmaceuticals (Nasdaq: LXRX) was trading nearly 36% lower on Friday morning. Markets were reacting to the outcome of the US Food and Drug Administration (FDA) ...
Morningstar1mon
Lexicon Pharmaceuticals Gets Negative FDA Panel Vote for Zynquista
Lexicon Pharmaceuticals received a negative vote from a Food and Drug Administration advisory committee for Zynquista as an adjunct to insulin therapy for glycemic control in adults with Type 1 ...
Business Insider1mon
Optimistic Buy Rating for Lexicon Pharmaceuticals Due to Positive Outlook on Sotagliflozin’s FDA Review
Joseph Pantginis has given his Buy rating due to a combination of factors surrounding Lexicon Pharmaceuticals’ sotagliflozin, which is under review by the FDA as an adjunct therapy for Type 1 ...
BioWorld1mon
Lexicon looks to go where no other oral drug has gone before
Lexicon Pharmaceuticals Inc. is counting on the Oct. 31 meeting of the U.S. FDA’s Endocrinologic and Metabolic Drugs Advisory Committee to help it break through the type 1 diabetes (T1D) door with ...